RecruitingNCT07455864

Lysosomal Acid Lipase Deficiency in Risk Groups

A Multicenter Real-world Observational Study of the Prevalence, Diagnostic Pathways, and Clinical Characteristics of Lysosomal Acid Lipase Deficiency in Pediatric and Adolescent Risk Groups in the Russian Federation (HELIOS)


Sponsor

AstraZeneca

Enrollment

1,200 participants

Start Date

Feb 25, 2026

Study Type

OBSERVATIONAL

Conditions

Summary

A multicenter real-world observational study of the prevalence, diagnostic pathways, and clinical characteristics of lysosomal acid lipase deficiency in pediatric and adolescent risk groups in the Russian Federation (HELIOS)


Eligibility

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a new treatment for people with lysosomal acid lipase deficiency. The study is currently recruiting participants at 4 locations.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.


Locations(4)

Research site

Nizhny Novgorod, Russia

Research Site

Petrozavodsk, Russia

Research Site

Rostov-on-Don, Russia

Research Site

Saint Petersburg, Russia

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07455864


Related Trials